A guide to epigenetics in leukaemia stem cells.
epigenetic plasticity
heterogeneity
leukaemia stem cells
myeloid neoplasms
single cell studies and multiomics
targeting LSC
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
11
08
2023
received:
19
04
2023
accepted:
20
10
2023
medline:
11
12
2023
pubmed:
24
10
2023
entrez:
24
10
2023
Statut:
ppublish
Résumé
Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity, combining information from recent studies assessing mutational, transcriptional and epigenetic landscapes at single cell resolution in myeloid neoplasms (MN). We highlight the importance of integrating epigenetic and genetic information to better understand inter- and intra-patient heterogeneity and discuss how this understanding further informs evolution and progression trajectories and subsequent clinical response in MN. Under this topic, we also discuss efforts to identify mechanisms of resistance, by longitudinal analyses of patient samples. Finally, we highlight how we might target these aberrant epigenetic processes for better therapeutic outcomes and to potentially eradicate LSCs.
Identifiants
pubmed: 37872885
doi: 10.1002/1878-0261.13544
pmc: PMC10701772
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2493-2506Subventions
Organisme : Wellcome Trust
ID : 203151/Z/16/Z
Pays : United Kingdom
Organisme : Cancer Research UK
ID : DRCRPG-Nov22/100014
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 218481/Z/19/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C49940/A25117
Pays : United Kingdom
Informations de copyright
© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Cancer Cell. 2015 Aug 10;28(2):198-209
pubmed: 26190263
Blood. 2018 Jun 14;131(24):2661-2669
pubmed: 29724899
Cancer Med. 2023 Apr;12(7):8956-8969
pubmed: 36545697
Nat Genet. 2023 Sep;55(9):1542-1554
pubmed: 37580596
Front Oncol. 2018 Jul 19;8:255
pubmed: 30073149
Nat Genet. 2021 Nov;53(11):1586-1596
pubmed: 34663924
Cell. 2019 Mar 7;176(6):1265-1281.e24
pubmed: 30827681
Nature. 1994 Feb 17;367(6464):645-8
pubmed: 7509044
Blood. 2023 Jan 12;141(2):156-167
pubmed: 35714312
Nature. 2022 Nov;611(7935):387-398
pubmed: 36289338
N Engl J Med. 2018 Jun 21;378(25):2386-2398
pubmed: 29860938
Cancers (Basel). 2020 Dec 12;12(12):
pubmed: 33322769
Cell Stem Cell. 2013 Mar 7;12(3):329-41
pubmed: 23333149
Nat Commun. 2020 Oct 21;11(1):5327
pubmed: 33087716
Nat Genet. 2022 Oct;54(10):1514-1526
pubmed: 36138229
Cancer Cell. 2010 Jan 19;17(1):13-27
pubmed: 20060365
Cell Stem Cell. 2015 Nov 5;17(5):585-96
pubmed: 26440282
Blood. 2019 Dec 12;134(24):2183-2194
pubmed: 31697807
Nat Struct Mol Biol. 2016 Jul;23(7):673-81
pubmed: 27294782
Curr Hematol Malig Rep. 2021 Feb;16(1):89-96
pubmed: 33630233
Blood. 2020 Sep 24;136(13):1507-1519
pubmed: 32556243
Blood. 2018 Apr 12;131(15):1730-1742
pubmed: 29453291
Nat Commun. 2021 Mar 23;12(1):1826
pubmed: 33758188
Nat Med. 2016 Jul;22(7):792-9
pubmed: 27322744
Nature. 2017 Nov 16;551(7680):384-388
pubmed: 29144447
Nat Rev Cancer. 2012 Sep;12(9):599-612
pubmed: 22898539
Nat Med. 2022 Jun;28(6):1212-1223
pubmed: 35618837
Nature. 2017 Jul 6;547(7661):104-108
pubmed: 28658204
Nature. 2022 Jun;606(7913):343-350
pubmed: 35650442
Mol Cell. 2018 Jan 18;69(2):279-291.e5
pubmed: 29351847
Nature. 2018 Jul;559(7715):637-641
pubmed: 30022161
Leukemia. 2014 Jun;28(6):1280-8
pubmed: 24270737
Cancer Discov. 2016 Oct;6(10):1106-1117
pubmed: 27520294
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11008-13
pubmed: 17576927
Sci Signal. 2017 Jan 31;10(464):
pubmed: 28143904
Mol Cell. 2016 Jun 2;62(5):695-711
pubmed: 27259202
Nature. 2020 Nov;587(7834):477-482
pubmed: 33116311
Cancer Cell. 2018 Nov 12;34(5):724-740.e4
pubmed: 30423294
Nat Med. 2016 Dec;22(12):1488-1495
pubmed: 27841873
Front Oncol. 2021 May 04;11:663406
pubmed: 34017684
Nat Med. 2020 Sep;26(9):1459-1467
pubmed: 32601337
Science. 2017 Jul 21;357(6348):
pubmed: 28729483
Mol Cell Proteomics. 2013 Mar;12(3):626-37
pubmed: 23233446
Int J Mol Sci. 2019 Jun 10;20(11):
pubmed: 31185600
J Clin Oncol. 2001 Apr 1;19(7):2033-40
pubmed: 11283136
Blood. 2018 Jan 18;131(3):328-341
pubmed: 29113963
Nat Med. 2017 Jan;23(1):69-78
pubmed: 27941792
Blood Adv. 2023 Jun 13;7(11):2504-2519
pubmed: 36705973
J Exp Med. 2019 Apr 1;216(4):966-981
pubmed: 30890554
Front Oncol. 2023 Mar 10;13:1149754
pubmed: 36969082
Nat Cancer. 2021 May;2(5):515-526
pubmed: 35122023
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Cell Stem Cell. 2010 Dec 3;7(6):708-17
pubmed: 21112565
Nature. 2023 Mar;615(7954):920-924
pubmed: 36922593